Palbociclib halts tumor growth in early breast cancer patients
A study has discovered that giving early breast cancer patients’ palbociclib alongside hormone treatment stopped tumor growth entirely.
Browsing: Clinical trials
ASH 2018 round-up: practice-changing data for leukemia subtype and more
Potentially practice-changing data was presented at 2018 ASH Annual Meeting and Exposition (December 1–4, 2018; CA, USA), read our round-up to discover the key studies. Highlights include the CASSINI and MAIA trial data,
Pancreatic Cancer Awareness Month – our highlights
November marks Pancreatic Cancer Awareness Month, to mark this occasion we have compiled our top content, highlighting advancements in diagnostic and treatment options for the disease.
Emerging treatment options for pancreatic cancer with Thomas Seufferlein
Thomas Seufferlein discusses diagnostic and treatment options for pancreatic cancer, as well as his thoughts on recent advancements, emerging treatments and trials, such as the TRYbeCA1 study.
SOLO-1: practice-changing results for advanced ovarian cancer patients with BRCA mutation
SOLO-1 is the first, double-blind, randomized, prospective Phase III trial to evaluate front-line olaparib maintenance therapy after platinum-based chemotherapy in newly diagnosed advanced ovarian cancer with BRCA mutation.
NCRI 2018: HiLo trial suggests low risk thyroid cancer patients can receive lower doses of radiation
Thyroid patients receiving low radiation doses presented similar recurrence rates compared to patients receiving high doses, the HiLo trial has demonstrated.
KEYNOTE-048: pembrolizumab changes the rules for head and neck cancer patients
Find out insider details of the KEYNOTE-048 study in this exclusive interview with first author of the study, Barbara Burtness.
ESMO18: New combination therapy for breast cancer may prolong survival
A major trial has demonstrated that fulvestrant–palbociclib combination therapy may prolong survival and delay the need for chemotherapy in women with advanced breast cancer.
It’s checkmate for Opdivo small-cell lung cancer trial
Bristol-Myers Squibb have recently announced the failure of the drug Opdivo® (nivolumab) to show a clinically significant effect in the treatment of small-cell lung cancer.
T-VEC: what’s next for oncolytic virotherapy and immuno-oncology?
Find out about T-VEC, which was the first oncolytic virotherapy that was approved by the FDA as well as the CheckMate 141 trial.
